Exploratory modelling track / In development
trajectoríes
Model and optimise the purification trajectory, rather than searching only for a single operating condition.
LNP / mRNA first.
The initial focus is heterogeneous lipid nanoparticles: target particles, partially loaded or unloaded populations, aggregates and free payload. AAV is a possible later application, not the core market.
Trajectories as the design object.
The proposed approach represents particle pathways through individual trajectories and uses their response to changing process conditions to design separation protocols. It does not assume that classical diffusion alone is the governing description. The relevant mechanisms and achievable selectivity remain to be demonstrated experimentally.
Differentiable computation.
The planned implementation uses JAX to compute and batch individual trajectories, differentiate model outputs with respect to process controls, and optimise time-dependent purification protocols. This is a computational development direction, not a validated experimental result.
From development to transfer.
Separation development service, technology transfer and method licensing form the initial business model. Platform licensing follows when methods and operating limits have been validated across use cases.
Performance target: cost per recovered usable product, assessed together with purity, recovery and throughput.